Recent Updates
Recently added Catalysts
RARE

Ultragenyx Announces Approval of Dojolvi (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

Wednesday, February 17, 2021 1 min read
Key Takeaway: Ultragenyx Announces Approval of Dojolvi (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

Full Press Release Details

Ultragenyx Announces Approval of Dojolvi (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children.
Tags: RARE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Feb 17, 2021